Fixed-combination brimonidine–timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study

References

• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
   PubMed Web of Science ®Google Scholar
• Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 2000;10:95-104
   PubMed Web of Science ®Google Scholar
• Netland PA, Landry T, Sullivan EK, et al. Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Schuman JS, Goldberg I, et al., for the Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002;120:1286-93
   PubMed Web of Science ®Google Scholar
• van der Valk R, Webers CAB, Schouten JSAG, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-85
   PubMed Web of Science ®Google Scholar
• Stewart WC, Konstas AG, Nelson LA, et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008;115:1117-22
   PubMed Web of Science ®Google Scholar
• Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin 2006;22:971-6
   PubMed Web of Science ®Google Scholar
• Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999;128:8-14
   PubMed Web of Science ®Google Scholar
• Goñi FJ, for the Brimonidine/Timolol Fixed Combination Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15:581-90
   PubMed Web of Science ®Google Scholar
• Sherwood MB, Craven ER, Chou C, et al., for the Combigan Study Groups I and II. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230-8
   PubMed Web of Science ®Google Scholar
• Hatanaka M, Grigera DE, Barbosa WL, et al. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. J Glaucoma 2008;17:674-9
   PubMed Web of Science ®Google Scholar
• Chauhan BC, Mikelberg FS, Artes PH, et al., for the Canadian Glaucoma Study Group. Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol 2010;128:1249-55
   PubMed Web of Science ®Google Scholar
• Nixon DR, Yan DB, Chartrand J-P, et al. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin 2009;25:1645-53
   PubMed Web of Science ®Google Scholar
• Le Henanff A, Giraudeau B, Baron G, et al. Quality of reporting of noninferiority and equivalence randomized trials. JAMA 2006;295:1147-51
   PubMed Web of Science ®Google Scholar
• Motolko MA. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr Med Res Opin 2008;24:2663-7
   PubMed Web of Science ®Google Scholar
• WoldeMussie E, Ruiz G, Wijono M, et al. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001;42:2849-55
   PubMed Web of Science ®Google Scholar
• Saylor M, McLoon LK, Harrison AR, et al. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol 2009;127:402-6
   PubMed Web of Science ®Google Scholar
• Krupin T, Liebmann JM, Greenfield DS, et al., on behalf of the Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011;151:671-81
   PubMed Web of Science ®Google Scholar